Liothyronine

( DrugBank: Liothyronine / KEGG DRUG: Liothyronine )

3 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2
210	Single Ventricle	1

ID	Disease name (Link within this page)	Number of trials
212	Tricuspid atresia	1

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02760056 (ClinicalTrials.gov)	June 6, 2016	5/4/2016	Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study	Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study	Multiple Sclerosis	Drug: Liothyronine sodium;Drug: Placebo	Oregon Health and Science University	NULL	Completed	18 Years	50 Years	All	15	Phase 1	United States
2	NCT02506751 (ClinicalTrials.gov)	July 2015	12/7/2015	Open-label Study of Liothyronine in MS	A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating A ...	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis ...	Drug: liothyronine	Johns Hopkins University	NULL	Completed	18 Years	58 Years	All	20	Phase 1	United States

Clinical trials : 51 / Drugs : 53 - (DrugBank : 22) / Drug target genes : 32 - Drug target pathways : 67

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004828 (ClinicalTrials.gov)	December 1994	24/2/2000	Liothyroninein Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan ...		Tricuspid Atresia;Heart Defects, Congenital	Drug: liothyronine I 131	FDA Office of Orphan Products Development	Children's Hospital and Health Center	Completed	N/A	17 Years	Both	28	Phase 1	NULL

Clinical trials : 5 / Drugs : 6 - (DrugBank : 6) / Drug target genes : 8 - Drug target pathways : 12

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004828 (ClinicalTrials.gov)	December 1994	24/2/2000	Liothyroninein Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan ...		Tricuspid Atresia;Heart Defects, Congenital	Drug: liothyronine I 131	FDA Office of Orphan Products Development	Children's Hospital and Health Center	Completed	N/A	17 Years	Both	28	Phase 1	NULL